Equities Analysts Offer Predictions for ABVX FY2024 Earnings

ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) - Equities researchers at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for ABIVAX Société Anonyme in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($2.93) per share for the year, up from their previous estimate of ($3.12). The consensus estimate for ABIVAX Société Anonyme's current full-year earnings is ($2.88) per share. Leerink Partnrs also issued estimates for ABIVAX Société Anonyme's FY2025 earnings at ($2.84) EPS, FY2026 earnings at ($1.69) EPS, FY2027 earnings at ($1.04) EPS and FY2028 earnings at ($0.80) EPS.

ABVX has been the subject of several other reports. JMP Securities reaffirmed a "market outperform" rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a "strong-buy" rating in a research note on Wednesday, December 4th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, ABIVAX Société Anonyme has a consensus rating of "Buy" and an average price target of $38.67.

ABIVAX Société Anonyme Stock Up 7.2 %

ABIVAX Société Anonyme stock traded up $0.46 during mid-day trading on Friday, reaching $6.76. 72,733 shares of the company were exchanged, compared to its average volume of 158,047. The firm's 50-day simple moving average is $7.03 and its two-hundred day simple moving average is $9.45. ABIVAX Société Anonyme has a twelve month low of $5.49 and a twelve month high of $17.02.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. GAMMA Investing LLC purchased a new stake in shares of ABIVAX Société Anonyme during the 4th quarter worth approximately $29,000. R Squared Ltd purchased a new stake in ABIVAX Société Anonyme during the fourth quarter worth $36,000. BNP Paribas Financial Markets grew its holdings in ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after purchasing an additional 5,900 shares during the last quarter. Walleye Capital LLC increased its position in shares of ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock valued at $2,965,000 after buying an additional 80,807 shares in the last quarter. Finally, abrdn plc raised its stake in shares of ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company's stock worth $3,645,000 after buying an additional 198,225 shares during the last quarter. Hedge funds and other institutional investors own 47.91% of the company's stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.